On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and safety of eneboparatide in adults with chronic hypoparathyroidi[...]
By using this site, you agree to the storage of cookies on your device for enhanced navigation, site analysis, and The TradingPub's marketing. Data sharing with social media platforms might occur based on the privacy choices you make on those platforms. For specifics, see our Privacy Policy.
